top of page
LATEST NEWS
What RMAT Designation Actually Means for a Gene Therapy
RMAT shows up in headline after headline. Here is what the FDA designation requires, what it gives developers, and the one thing it does not mean.
3 hours ago3 min read


FDA Grants RMAT to Kamau's Sickle Cell Therapy That Corrects the Mutation Itself
Nula-cel repairs the sickle mutation in a patient's own stem cells rather than switching on fetal hemoglobin. All three patients on the optimized process are transfusion-free with no pain crises.
1 day ago3 min read


A Cancer-Killing Virus Cut Bladder Cancer Recurrence by 68% in a Phase 3 Trial
CG Oncology's cretostimogene reduced the risk of recurrence by 68% versus surveillance in 367 patients with intermediate-risk bladder cancer, with no serious treatment-related side effects.
2 days ago3 min read


LEARN MORE
LEARN MORE

GENE TECH TIMES
The Future Has Arrived


One CRISPR Infusion Cut Triglycerides 63% in People With Severe Hypertriglyceridemia
At AHA 2026, CRISPR Therapeutics reported that one fixed dose of CTX310 lowered ANGPTL3 by 65% and triglycerides by 63% in 10 people with severe hypertriglyceridemia, with no treatment-related serious side effects.
Nov 10


One CRISPR Infusion Kept Cholesterol and Triglycerides Down for a Full Year
One-year data for CTX310, a single-infusion CRISPR therapy that switches off ANGPTL3 in the liver, showed LDL cholesterol down 53% and triglycerides down 48% at the top dose, with no treatment-related serious side effects.
Oct 5
bottom of page


